TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7814240
Drug: High-fat spread
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat spread (80% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group C)
Study: 322782
Drug: Haloperidol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3 mg daily)
Study: 29737733
Drug: Voice training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice training (6 hours of intensive vocal therapy one week before surgery)
Study: 17845590
Drug: Budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5 microg b.i.d. plus additional doses as needed (SMART)
Study: 9424683
Drug: Methadone (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (Group M) - 9 mg‐18 mg/24 h in epidural perfusion
Study: 7946161
Drug: doxazosin, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxazosin, 4 mg daily
Study: 3429068
Drug: Sulbenicillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbenicillin (2 g i.m. every 12 h for 7 days)
Study: 3429068
Drug: Piperacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (2 g i.m. every 12 h for 7 days)
Study: 29274733
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Treatment (CRT)
Study: 29164824
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Treatment (CRT) plus Motivational Interviewing (MI)
Study: 29037157
Drug: TEA with
Normalized name: MENTHOL 4.1 mg ORAL LOZENGE [SUGAR FREE GREEN TEA WITH ECHINACEA COUGH SUPPRESSANT THROAT DROPS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEA with ropivacaine and morphine (Ep-RM)
Study: 29037157
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (IV-M)
Study: 23165172
Drug: Physiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy plus botulinum toxin injection (BTX)
Study: 21118844
Drug: Remifentanil 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0 µg kg⁻¹ min⁻¹
Study: 21118844
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 µg kg⁻¹ min⁻¹
Study: 21118844
Drug: Remifentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.0 µg kg⁻¹ min⁻¹
Study: 21118844
Drug: Remifentanil administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil administration
Study: 16539549
Drug: Preemptive valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive valdecoxib 40 mg at least 30 minutes before initial archwire placement
Study: 16539549
Drug: Postoperative valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative valdecoxib 40 mg two hours after initial archwire placement
Study: 12907532
Drug: Warmed nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed nasal PD solutions (37 degrees C)
Study: 12907532
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature nasal PD solutions (22 degrees C)
Study: 10638382
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of 4-androstene-3,17-dione (delta 4)
Study: 10638382
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of 4-androstene-3 beta,17 beta‐diol (delta 4 Diol)
Study: 8761562
Drug: Daily surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily surveillance for illness and fortnightly malaria surveys in Group 1 schoolchildren.
Study: 8761562
Drug: Two-monthly surveys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-monthly surveys and weekly home visits in Group 2 subjects.
Study: 3213310
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg fenoterol orally before PGE2-gel application
Study: 3213310
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet before PGE2-gel application
Study: 28116968
Drug: Subacromial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subacromial infusion of local anesthetic (CSIA)
Study: 19889524
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + PS (2 g/day)
Study: 17337065
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of 24 Gy or higher
Study: 2568210
Drug: MK-912 2
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-912 2 mg
Study: 2568210
Drug: MK-912 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-912 0.2 mg
Study: 31374015
Drug: Xinnaoning capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinnaoning capsule (3 pills, 3 times daily for 12 weeks)
Study: 28874142
Drug: cART with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: cART with 800 mg efavirenz
Study: 10875050
Drug: Paroxetine (20‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20‐50 mg/day)
Study: 10875050
Drug: Paroxetine (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20, 40, or 60 mg/day)
Study: 1399203
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg terbinafine twice daily
Study: 1399203
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg terbinafine once daily
Study: 30742915
Drug: Combination controller
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination controller therapy
Study: 22154417
Drug: Magnetically guided
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetically guided capsule endoscope (MGCE)
Study: 18617486
Drug: Oral co‐trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co‐trimoxazole (per protocol analysis)
Study: 27945464
Drug: Cevimeline 30
Normalized name: Cevimeline 30mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevimeline 30 mg TID (escalated to 45 mg TID if no improvement)
Study: 11815395
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg daily for 2 months)
Study: 10355512
Drug: Lansoprazole (LNS)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d. + metronidazole (MTR) 250 mg q.i.d.
Study: 10355512
Drug: Lansoprazole (LNS)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LNS) 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.
Study: 10355512
Drug: Lansoprazole (LNS)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LNS) 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d.
Study: 8952741
Drug: Cibenzoline (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (260 mg/day, reduced to 130 mg/day for elderly patients)
Study: 8952741
Drug: Propafenone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (600 mg/day, reduced to 300 mg/day for elderly patients)
Study: 1682159
Drug: 120mg terfenadine
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg terfenadine twice daily for 4 weeks
Study: 6756798
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (halcinonide ointment, 0.1 percent)
Study: 6756798
Drug: Placebo (ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ointment base)
Study: 28352069
Drug: N-Butylphthalide and
Normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Butylphthalide and hyperbaric oxygen therapy (HBO)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (patients >58 years of age)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (APACHE II score >22)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (diabetic patients)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (patients on vasopressor therapy)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (admitted with severe sepsis)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (creatinine ≤ 100 μmol/L)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (GCS ≤ 9)
Study: 21819615
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (simvastatin, equipotent doses ≥ 40 mg)
Study: 20048489
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection with hyaluronic acid (HA) + standard of care (RICE)
Study: 20048489
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (PL) + standard of care (RICE)
Study: 17334536
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg for 5 days)
Study: 17334536
Drug: Lansoprazole treatment
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole treatment in H. pylori-positive group
Study: 11280168
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 g/kg body wt)
Study: 9426843
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) 3,200 mg/day for 3 months
Study: 2949910
Drug: Human alpha-ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human alpha-ANP (1-28) infusion at 1.2 pmol min-1 kg-1 for 3 hours
Study: 2949910
Drug: Human alpha-ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human alpha-ANP (1-28) infusion
Study: 30629020
Drug: Enhanced recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced recovery (nonopioid analgesia, patient-directed oral intake, early ambulation)
Study: 30629020
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (opioid analgesia, physician-directed diet)
Study: 30503129
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone co-treatment during IVF
Study: 20002592
Drug: Optimized antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized antidepressant therapy for both depression and pain
Study: 2145237
Drug: Enoximone, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone, 100 mg t.d.s. added to optimal therapy
Study: 30936865
Drug: Dairy protein
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy protein supplement (6 grams/packet, twice per day for 8 weeks)
Study: 30936865
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplement (6 grams/packet, twice per day for 8 weeks)
Study: 27614706
Drug: Sequential Amplatz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Amplatz dilation
Study: 21462258
Drug: Dopaminergic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medications
Study: 16037752
Drug: Combined esterified
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined esterified estrogens (1.25 mg) and methyltestosterone (2.5 mg) (EE/MT)
Study: 16037752
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens (1.25 mg) alone (EE)
Study: 12151959
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 days 1-3 and vinorelbine 25 mg/m2 days 1 and 8 without filgrastim
Study: 12151959
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 days 1-3 and vinorelbine 25 mg/m2 days 1 and 8 with filgrastim
Study: 10065780
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg/d; n = 14)
Study: 10065780
Drug: CPA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA (25 mg plus ethinyl E2 (EE); n = 13)
Study: 10065780
Drug: Flutamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (500 mg/d; n = 15)
Study: 8640470
Drug: Non-suture method
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-suture method (Monsel's solution pack)
Study: 6778456
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate in combination with low doses of lithium
Study: 22894553
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg per day)
Study: 11751182
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microg twice daily)
Study: 10335001
Drug: Terbutaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (1 mg four times daily)
Study: 7567317
Drug: Ceftibuten oral
Normalized name: ceftibuten Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten oral suspension at a dose of 9.0 mg/kg
Study: 7567317
Drug: Ceftibuten oral
Normalized name: ceftibuten Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten oral suspension at doses of 4.5, 9.0, and 13.5 mg/kg
Study: 7567317
Drug: Ceftibuten oral
Normalized name: ceftibuten Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten oral suspension
Study: 31944893
Drug: Dental RECUR
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dental RECUR Brief Negotiated Interview for Oral Health (DR‐BNI)
Study: 29197345
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg and Etoricoxib 120 mg
Study: 19666639
Drug: Warfarin suspended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin suspended 3 days before surgery (Group 1)
Study: 19666639
Drug: Warfarin suspended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin suspended <3 days or not at all (Group 2)
Study: 19666639
Drug: Post-operation heparin
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operation heparin treatment
Study: 19666639
Drug: Proposed protocol
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed protocol of perioperative anticoagulation (suspension of warfarin not <3 days with low-molecular-weight heparin bridging stopped 12 h before surgery)
Study: 17203292
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg oral dose (PO)
Study: 17203292
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg intravenous dose (IV)
Study: 15213052
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (30 g ethanol/d for 28 days)
Study: 29232214
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection above the median nerve
Study: 29232214
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection below the median nerve
Study: 10342407
Drug: Opioids (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (specific dosage and duration not mentioned)
Study: 7739306
Drug: 585 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585 nm flashlamp‐pumped pulsed‐dye laser treatment
Study: 30927415
Drug: GnRHa trigger
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRHa trigger (buserelin 0.5 mg)
Study: 26742509
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) - 78‐234 mg, monthly injectable
Study: 26742509
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (OA) - daily treatment
Study: 22443173
Drug: Metformin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (250 mg per day)
Study: 17919541
Drug: Inhaled zanamivir
Normalized name: zanamivir Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled zanamivir 10 mg once daily for 28 days
Study: 10915082
Drug: 5-day oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day oral antibiotics
Study: 8955760
Drug: Ibopamine 100
Normalized name: ibopamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine 100 mg/day (group A)
Study: 4000532
Drug: Tiropramide hydrochloride
Normalized name: tiropramide hydrochloride
DrugBank: Tiropramide (DB13091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiropramide hydrochloride 100 mg t.i.d. for 4 weeks
Study: 31056840
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg danirixin hydrobromide
Study: 31056840
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg danirixin hydrobromide
Study: 31056840
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg danirixin hydrobromide
Study: 31056840
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg danirixin hydrobromide (fed state - low-fat meal)
Study: 19478822
Drug: Control (observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (observation or photodynamic therapy)
Study: 17963760
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (ferrous sulfate tablet containing 50 mg elemental iron daily)
Study: 14641799
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) once daily for five consecutive days
Study: 1593553
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal suppositories of 10 mg of prostaglandin E2 (17 patients)
Study: 1593553
Drug: Daily intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravesical solution of 50 micrograms of prostaglandin F2 alpha dissolved in 100 mL of normal saline (15 patients)
Study: 1593553
Drug: Daily instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily instillation of 100 mL of saline (18 patients)
Study: 27992112
Drug: BAY 94-9027
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 94-9027 (every-5-days treatment)
Study: 25530148
Drug: Treatment participants
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment participants (SPs)
Study: 23387374
Drug: 2% tofacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% tofacitinib ointment 1
Study: 23387374
Drug: 2% tofacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% tofacitinib ointment 2
Study: 21429214
Drug: HDC/IL‐2 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDC/IL‐2 treatment
Study: 19320915
Drug: Risk-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-based oral health programme (OHP) targeting MS-positive subjects, involving repeated health education for caretakers and xylitol lozenges for children.
Study: 19320915
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral health programme (control group).
Study: 11240075
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg bid
Study: 11240075
Drug: Dihydrocodeine 60
Normalized name: dihydrocodeine bitartrate 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine 60 mg bid
Study: 8033491
Drug: MK-0591 250
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 250 mg every morning for 10 days
Study: 8033491
Drug: MK-0591 50
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 50 mg every morning for 10 days
Study: 8033491
Drug: MK-0591 125
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 125 mg every morning for 10 days
Study: 8033491
Drug: MK-0591 250
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 250 mg every 12 hours for 10 days
Study: 8033491
Drug: MK-0591 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 (all doses)
Study: 2567113
Drug: Dilevalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (200 to 1,600 mg once daily)
Study: 2567113
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 to 400 mg once daily)
Study: 23203241
Drug: Pregabalin, starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin, starting at 150 mg/day, increasing to 300 or 450 mg/day
Study: 15129933
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (3 x 10-g doses for 7 days)
Study: 8967905
Drug: Trapidil 200
Normalized name: trapidil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil 200 mg t.i.d.
Study: 9134282
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg t.i.d.
Study: 7946235
Drug: Work therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work therapy stations
Study: 3284488
Drug: Co-trimoxazole (CTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (CTZ) 480 mg three times a day for 24 weeks
Study: 3284488
Drug: Sulphapyridine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphapyridine 1.25 g a day
Study: 25768057
Drug: Unilateral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral sequential endoscopic thoracic sympathectomy (S‐ETS)
Study: 17179734
Drug: AST‐120 co‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST‐120 co‐administered with ongoing treatment
Study: 17179734
Drug: Ongoing treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing treatments only (control group)
Study: 10222447
Drug: pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole (40 mg)
Study: 10222447
Drug: omeprazole MUPS
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole MUPS (20 mg)
Study: 2331418
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine (10 micrograms) administered alone